Zacks Research Weighs in on Clorox’s Q3 Earnings (NYSE:CLX)

The Clorox Company (NYSE:CLX) – Zacks Research lowered their Q3 2025 earnings estimates for shares of Clorox in a note issued to investors on Monday, February 17th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.60 for the quarter, down from their previous estimate of $1.68. The consensus estimate for Clorox’s current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox’s Q4 2025 earnings at $2.14 EPS, FY2025 earnings at $7.15 EPS, Q1 2026 earnings at $1.63 EPS, Q2 2026 earnings at $1.64 EPS, Q3 2026 earnings at $1.66 EPS, FY2026 earnings at $7.12 EPS, Q1 2027 earnings at $1.74 EPS, Q2 2027 earnings at $1.76 EPS and FY2027 earnings at $7.64 EPS.

CLX has been the subject of several other reports. Barclays raised their price target on shares of Clorox from $130.00 to $140.00 and gave the stock an “underweight” rating in a research note on Wednesday, February 5th. DA Davidson decreased their price target on shares of Clorox from $171.00 to $169.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Wells Fargo & Company raised their price target on shares of Clorox from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 4th. JPMorgan Chase & Co. raised their target price on shares of Clorox from $171.00 to $173.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $150.00 target price on shares of Clorox in a research note on Thursday, January 30th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $158.21.

Clorox Price Performance

Shares of CLX opened at $150.93 on Wednesday. The stock has a market capitalization of $18.68 billion, a P/E ratio of 41.24, a P/E/G ratio of 2.53 and a beta of 0.42. Clorox has a twelve month low of $127.60 and a twelve month high of $171.37. The company has a 50 day moving average of $158.38 and a 200-day moving average of $159.74. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Monday, February 3rd. The company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.16. Clorox had a net margin of 6.38% and a return on equity of 316.87%. During the same quarter in the previous year, the company posted $2.16 earnings per share.

Hedge Funds Weigh In On Clorox

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLX. Wealth Group Ltd. bought a new position in Clorox during the third quarter worth $231,000. Creative Planning lifted its holdings in shares of Clorox by 7.4% during the third quarter. Creative Planning now owns 29,089 shares of the company’s stock worth $4,739,000 after buying an additional 1,996 shares in the last quarter. Bleakley Financial Group LLC lifted its holdings in shares of Clorox by 3.0% during the third quarter. Bleakley Financial Group LLC now owns 4,392 shares of the company’s stock worth $716,000 after buying an additional 126 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Clorox by 12.5% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,857 shares of the company’s stock worth $2,095,000 after buying an additional 1,427 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Clorox by 34.7% during the third quarter. Blue Trust Inc. now owns 913 shares of the company’s stock worth $149,000 after buying an additional 235 shares in the last quarter. 78.53% of the stock is owned by institutional investors.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.